In Vitro Maturation (IVM) for Polycystic Ovary Syndrome (PCOS)
Not Applicable
Completed
- Conditions
- Polycystic Ovarian Syndrome
- Registration Number
- NCT01237106
- Lead Sponsor
- University Reproductive Associates
- Brief Summary
This pilot study will be a prospective investigation to study the efficacy and safety of In-Vitro Maturation (IVM) for women with Polycystic Ovarian Syndrome (PCOS). There will be 10 subjects total in this Study. There will be no blinding to treatment.
In-Vitro Maturation will provide a viable, safe option for women with PCOS attempting pregnancy through the use of Assisted Reproductive Technology (ART).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Incidence of Biochemical Pregnancy (defined as a rising Beta-HCG level). 6 months
- Secondary Outcome Measures
Name Time Method Incidence of Ovarian Hyperstimulation Syndrome (OHSS) 6 months live births 1 1/2 years number of immature oocytes retrieved 6 months rates of maturation and fertilization 6 months
Trial Locations
- Locations (1)
University Reproductive Associates
🇺🇸Hoboken, New Jersey, United States
University Reproductive Associates🇺🇸Hoboken, New Jersey, United States